Navigation Links
Misonix Announces New Distribution Agreement for Chile
Date:8/1/2011

FARMINGDALE, N.Y., Aug. 1, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has entered into a new three-year exclusive distribution agreement with Osteotrauma Ltda., based in Concepcion, Chile. Osteotrauma will sell and distribute the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter throughout Chile. The agreement includes annual minimum purchase requirements.  

Osteotrauma has earned a reputation for introducing high tech, state-of-the-art medical devices to the Chilean market and is respected for their commitment to excellence in customer service. Osteotrauma supplies a wide range of specialty medical products to the Chilean market with a focus on neurosurgery and spine surgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.

"Misonix is pleased to add Osteotrauma to our sales family as we put the finishing touches on our Latin American distribution network.  Their reputation as a quality distributor of medical equipment and devices in Chile is well established," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their success in introducing new medical devices, as well as their commitment to customer service, was appealing to Misonix.  We are particularly pleased that they will be selling two of our key products through their distribution network."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Announces Settlement of PuriCore Litigation, Including Entry into a U.S. Distribution Agreement for PuriCores Advanced Wound Care Product
2. Misonix Announces Exclusive U.S. Distribution Agreement For Advanced Wound Care Product
3. Misonix Schedules Third Quarter 2011 Financial Results Conference Call; May 10, 2011 at 11:30 A.M. Eastern
4. Misonix to Present at the MDB Capital Bright Lights Conference on May 11, 2011
5. Misonix Exhibits at Annual APTA-CSM Meeting
6. Misonix Announces New Distribution Agreement for Colombia
7. Misonix Announces Change in Distribution of BoneScalpel™ Bone Cutting System in the U.S.
8. Misonix to Present at the ROTH Capital Growth Stock Conference on March 15, 2011
9. Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results
10. Misonix Announces Completion of Product Registrations in Key Latin American Markets
11. Misonix Schedules Second Quarter 2011 Financial Results Conference Call; February 9, 2011 at 4:30 p.m. Eastern
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... May 22, 2017 , ... ... on Wellocity to empower WeightZone Factor members to track their exercise patterns, monitor ... excellent health education, all on their mobile phones. It also provides social networks ...
(Date:5/21/2017)... ... 2017 , ... Chris Cornell, 52, was found dead on the night of Wednesday, May 17, ... lead singers in the rock industry would take his own life, but the extremely talented ... mental illness played a role in the death of Chris Cornell . , Depression ...
(Date:5/21/2017)... , ... May 20, 2017 , ... ... systems between ABC Financial Services and financial systems. , Dozens of ... exported files that are electronically processed through GetLinked into their club’s accounting system ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pot. Reefer. Grass. Mary Jane. No matter what ... its attributes like never before. More than a map, new social marketplace Weedable ... strains, products – and for the first time – each other. A social marketplace ...
(Date:5/21/2017)... ... May 21, 2017 , ... Florida Pain Relief Group, a division of Physician ... at 109 Silver Palm Ave., Melbourne, on Monday, May 22. Initially the clinic will ... the Melbourne practice, PPOA operates 23 pain management clinics in Florida and the Dallas-Fort ...
Breaking Medicine News(10 mins):